

# HNE AREA Intensive Care

Approved For: JHH and CMN ICU's

## Pethidine Hydrochloride

**Trade Name:**

**Presentation:** 100mg/2ml ampoule

**Indications:** To be used in the Cerebral Hypothermia in ischaemic Lesion (CHIL) trial **only for the control of shivering.**

**The pethidine together with buspirone will be kept in the zone B Dangerous drugs Cupboard**

**Administration;** In accordance with the CHIL study protocol.

**Startup Bolus:** up to 1 mg /kg (max 100mg) slowly see CHIL protocol table

**Subsequent bolus:** 10 to 25mg see CHIL protocol table.(this 1 to 2.5 ml of infusion solution )

**Infusion:** 500mg pethidine in 50ml delivered via syringe driver (concentration 10mg/ml) N.B. 4mg/hr is 0.4ml/hr

The maximum infusion rate generally 0.4mg/kg/hr, however this must be titrated to level of sedation.

**Dose** infusion max 0.4mg/kg/hr

**Precautions** Hourly sedation must be scored and documented - see CHIL protocol for adjustment of pethidine infusion. Sedation Score of +1 or greater requires medical review.

Resuscitative equipment and narcotic antagonist should be readily available.

Contra-indicated in severe liver disease or with MAO therapy. Norpethidine accumulates in renal failure

**Compatibilities:** Crystalloids

---

Created: 20-Mar-09 by Dr K Havill Reviewed: 20-Mar-09 by Dr K Havill Guideline to be reviewed before : 30-Jul-09

These guidelines are intended for and to be used only by experienced critical care staff under direct supervision of Hunter Health Area Intensive Care Specialists in designated Hunter Health Area Critical Care Areas. The Authors will not be responsible for inappropriate use of these guidelines